⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 8, 2025

Figure S13 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Zahra Davoudi Thomas S. Dexheimer Nathan P. Coussens Thomas Silvers Raymond G. Fox Samantha B. Kemp Poorva Juneja Joel Morris Melinda G. Hollingshead Naoko Takebe James H. Doroshow Beverly A. Teicher

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination treatment shows promising activity against multicell-type tumor spheroids with oncogenic KRAS.
The interaction between BI-3406 and sapanisertib demonstrates an effective therapeutic strategy.
This approach targets multiple cancer types using patient-derived models and supports personalized medicine.
Findings may influence future clinical applications and trials involving RAS pathway inhibitors.

Implication

Combination therapy improves effectiveness in patient-derived spheroids with oncogenic KRAS variants, highlighting potential treatment advancements.

Abstract

Figure S13. Combination activity of BI-3406 with sapanisertib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3b9e https://doi.org/10.1158/2767-9764.30304711

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
2Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
3Figure S8 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
4Figure S11 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
5Figure S7 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025